These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

351 related items for PubMed ID: 17826411

  • 21. Management of recurrent preterm labor in twin gestations with nifedipine tocolysis.
    de la Torre L, Istwan NB, Desch C, Rhea DJ, Roca L, Stanziano GJ, González-Quintero VH.
    Am J Perinatol; 2008 Oct; 25(9):555-60. PubMed ID: 18773381
    [Abstract] [Full Text] [Related]

  • 22. Preterm birth prevention by 17 alpha-hydroxyprogesterone caproate vs. daily nursing surveillance.
    Rittenberg C, Newman RB, Istwan NB, Rhea DJ, Stanziano GJ.
    J Reprod Med; 2009 Feb; 54(2):47-52. PubMed ID: 19301566
    [Abstract] [Full Text] [Related]

  • 23. Pregnancy and economic outcomes in patients treated for recurrent preterm labor.
    Fleming A, Bonebrake R, Istwan N, Rhea D, Coleman S, Stanziano G.
    J Perinatol; 2004 Apr; 24(4):223-7. PubMed ID: 14999214
    [Abstract] [Full Text] [Related]

  • 24. 17-alpha Hydroxyprogesterone caproate did not reduce the rate of recurrent preterm birth in a prospective cohort study.
    Nelson DB, McIntire DD, McDonald J, Gard J, Turrichi P, Leveno KJ.
    Am J Obstet Gynecol; 2017 Jun; 216(6):600.e1-600.e9. PubMed ID: 28223163
    [Abstract] [Full Text] [Related]

  • 25. 17-alphahydroxyprogesterone caproate in women with previous spontaneous preterm delivery: does a previous term delivery affect the rate of recurrence?
    Barton JR, Barton LA, Istwan NB, Rhea DJ, Desch CN, Sibai BM.
    Am J Obstet Gynecol; 2011 Sep; 205(3):269.e1-6. PubMed ID: 22071060
    [Abstract] [Full Text] [Related]

  • 26. A randomised controlled trial of metronidazole for the prevention of preterm birth in women positive for cervicovaginal fetal fibronectin: the PREMET Study.
    Shennan A, Crawshaw S, Briley A, Hawken J, Seed P, Jones G, Poston L.
    BJOG; 2006 Jan; 113(1):65-74. PubMed ID: 16398774
    [Abstract] [Full Text] [Related]

  • 27. 17α Hydroxyprogesterone caproate for prevention of recurrent spontaneous preterm birth.
    Merlob P, Stahl B, Klinger G.
    Reprod Toxicol; 2012 Jan; 33(1):15-9. PubMed ID: 22120850
    [Abstract] [Full Text] [Related]

  • 28. 17 hydroxyprogesterone for the prevention of preterm delivery.
    Meis PJ, Society for Maternal-Fetal Medicine.
    Obstet Gynecol; 2005 May; 105(5 Pt 1):1128-35. PubMed ID: 15863556
    [Abstract] [Full Text] [Related]

  • 29. Impact of 17P usage on NICU admissions in a managed medicaid population--a five-year review.
    Mason MV, Poole-Yaeger A, Krueger CR, House KM, Lucas B.
    Manag Care; 2010 Feb; 19(2):46-52. PubMed ID: 20550052
    [Abstract] [Full Text] [Related]

  • 30. Gestational age of previous twin preterm birth as a predictor for subsequent singleton preterm birth.
    Rafael TJ, Hoffman MK, Leiby BE, Berghella V.
    Am J Obstet Gynecol; 2012 Feb; 206(2):156.e1-6. PubMed ID: 22098669
    [Abstract] [Full Text] [Related]

  • 31. Nonresponse to 17-alpha hydroxyprogesterone caproate for recurrent spontaneous preterm birth prevention: clinical prediction and generation of a risk scoring system.
    Manuck TA, Stoddard GJ, Fry RC, Esplin MS, Varner MW.
    Am J Obstet Gynecol; 2016 Nov; 215(5):622.e1-622.e8. PubMed ID: 27418444
    [Abstract] [Full Text] [Related]

  • 32. Early and late preterm delivery rates - a comparison of differing tocolytic policies in a single urban population.
    Hehir MP, O'Connor HD, Kent EM, Robson MS, Keane DP, Geary MP, Malone FD.
    J Matern Fetal Neonatal Med; 2012 Nov; 25(11):2234-6. PubMed ID: 22524700
    [Abstract] [Full Text] [Related]

  • 33. 17-α hydroxyprogesterone caproate for the prevention of preterm birth.
    Gupta S, Roman AS.
    Womens Health (Lond); 2012 Jan; 8(1):21-30. PubMed ID: 22171770
    [Abstract] [Full Text] [Related]

  • 34. The use of progestational agents for preterm birth: lessons from a mouse model.
    Elovitz MA, Mrinalini C.
    Am J Obstet Gynecol; 2006 Oct; 195(4):1004-10. PubMed ID: 17000233
    [Abstract] [Full Text] [Related]

  • 35. Relation of body mass index to frequency of recurrent preterm birth in women treated with 17-alpha hydroxyprogesterone caproate.
    Co AL, Walker HC, Hade EM, Iams JD.
    Am J Obstet Gynecol; 2015 Aug; 213(2):233.e1-5. PubMed ID: 25912300
    [Abstract] [Full Text] [Related]

  • 36. A randomised controlled double-blind clinical trial of 17-hydroxyprogesterone caproate for the prevention of preterm birth in twin gestation (PROGESTWIN): evidence for reduced neonatal morbidity.
    Awwad J, Usta IM, Ghazeeri G, Yacoub N, Succar J, Hayek S, Saasouh W, Nassar AH.
    BJOG; 2015 Jan; 122(1):71-9. PubMed ID: 25163819
    [Abstract] [Full Text] [Related]

  • 37. Effectiveness of 17-α-hydroxyprogesterone caproate on preterm birth prevention in women with history-indicated cerclage.
    Mackeen AD, Rafael TJ, Zavodnick J, Berghella V.
    Am J Perinatol; 2013 Oct; 30(9):755-8. PubMed ID: 23341330
    [Abstract] [Full Text] [Related]

  • 38. Pregnancy outcomes of women receiving compounded 17 α-hydroxyprogesterone caproate for prophylactic prevention of preterm birth 2004 to 2011.
    Sibai BM, Istwan NB, Palmer B, Stanziano GJ.
    Am J Perinatol; 2012 Sep; 29(8):635-42. PubMed ID: 22576126
    [Abstract] [Full Text] [Related]

  • 39. Does indomethacin prevent preterm birth in women with cervical dilatation in the second trimester?
    Berghella V, Prasertcharoensuk W, Cotter A, Rasanen J, Mittal S, Chaithongwongwatthana S, Gomez R, Kearney E, Tolosa JE, Pereira L.
    Am J Perinatol; 2009 Jan; 26(1):13-9. PubMed ID: 19021101
    [Abstract] [Full Text] [Related]

  • 40. Managing perinatal outcomes: the clinical benefit and cost-effectiveness of pharmacologic treatment of recurrent preterm labor.
    Lam F, Istwan NB, Jacques D, Coleman SK, Stanziano GJ.
    Manag Care; 2003 Jul; 12(7):39-46. PubMed ID: 12891954
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 18.